Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of buparlisib in relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
2012-002208-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), sponsored by Novartis. Primary endpoint: Objective response rate. Started Dec 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-002208-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002208-41.